| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 401.003.473 $ | -28.161.817 $ | -12,9 % | 3 | 429.165.290 $ | +75.679.359 $ | +36,7 % | 3 | 353.485.931 $ | +194.993.219 $ | +116,8 % | 3 | ||||
| Rapport Therapeutics, Inc. | RAPP | → 0 | Neutral | 223.261.441 $ | +6.778.472 $ | +3,1 % | 1 | 216.482.969 $ | +4.566.549 $ | +2,2 % | 1 | 211.916.420 $ | +130.788.821 $ | +161,2 % | 1 |
| Septerna, Inc. | SEPN | → 0 | Neutral | 149.360.652 $ | -23.930.025 $ | -13,8 % | 1 | 173.290.677 $ | +56.375.410 $ | +48,2 % | 1 | 116.915.267 $ | +51.216.470 $ | +78,0 % | 1 |
| Maze Therapeutics, Inc. | MAZE | → 0 | Sehr schwach | 28.381.380 $ | -11.010.264 $ | -28,0 % | 1 | 39.391.644 $ | +14.737.400 $ | +59,8 % | 1 | 24.654.244 $ | +12.987.928 $ | +111,3 % | 1 |
| 401.003.473 $ | -28.161.817 $ | -12,9 % | 3 | 429.165.290 $ | +75.679.359 $ | +36,7 % | 3 | 353.485.931 $ | +194.993.219 $ | +116,8 % | 3 | ||||